William Blair Issues Positive Estimate for LH Earnings

Laboratory Co. of America Holdings (NYSE:LH) – Investment analysts at William Blair upped their Q2 2025 earnings per share estimates for shares of Laboratory Co. of America in a research report issued on Monday, February 10th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings of $4.00 per share for the quarter, up from their prior estimate of $3.92. The consensus estimate for Laboratory Co. of America’s current full-year earnings is $15.96 per share.

LH has been the subject of several other research reports. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their price target for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Jefferies Financial Group raised their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 6th. UBS Group decreased their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Bank of America lifted their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Finally, Barclays decreased their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a research report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $265.31.

Laboratory Co. of America Trading Down 1.7 %

Shares of Laboratory Co. of America stock opened at $241.05 on Thursday. Laboratory Co. of America has a twelve month low of $191.97 and a twelve month high of $258.59. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $236.92 and a 200-day moving average price of $230.55. The firm has a market cap of $20.16 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 1.84 and a beta of 1.07.

Laboratory Co. of America (NYSE:LH) last posted its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%.

Laboratory Co. of America Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s payout ratio is currently 32.65%.

Insider Buying and Selling at Laboratory Co. of America

In other news, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the sale, the director now owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. The trade was a 7.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Amy B. Summy sold 3,672 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $238.91, for a total value of $877,277.52. Following the completion of the sale, the chief marketing officer now owns 4,318 shares of the company’s stock, valued at $1,031,613.38. The trade was a 45.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,383 shares of company stock valued at $4,408,373 in the last quarter. 0.85% of the stock is owned by insiders.

Institutional Investors Weigh In On Laboratory Co. of America

A number of institutional investors and hedge funds have recently bought and sold shares of the company. OneDigital Investment Advisors LLC increased its stake in shares of Laboratory Co. of America by 115.7% during the third quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company’s stock valued at $1,361,000 after buying an additional 3,265 shares during the period. Alexander Randolph Advisory Inc. purchased a new position in Laboratory Co. of America during the 3rd quarter valued at about $955,000. Wealthcare Advisory Partners LLC raised its holdings in shares of Laboratory Co. of America by 23.9% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company’s stock valued at $583,000 after purchasing an additional 490 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in shares of Laboratory Co. of America in the 3rd quarter valued at about $2,316,000. Finally, Barclays PLC lifted its position in shares of Laboratory Co. of America by 11.8% in the 3rd quarter. Barclays PLC now owns 620,721 shares of the medical research company’s stock worth $138,718,000 after purchasing an additional 65,356 shares during the period. 95.94% of the stock is owned by institutional investors.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.